U.S. Department of Continerce Patent and Trademark Office

O P FINFORMATION DISCLOSURE

STATEMENT

Attorney Docket No. 29915/6280N3	Serial 10/65		
Applicant Gurney et al.			
Filing Date August 29, 2003	Group	1645-	1649

TRADEN	M		TIC DAT	PENER DOCUMENTO			· · · · · · · · · · · · · · · · · · ·
		T 5		TENT DOCUMENTS	Class	Cubalaga	Pili- Data
*Examir		Document Number	Issue Date	Name	Class	Subclass	Filing Date If
Initials	·	Number	Date				Appropriate
							Appropriate
GE	Al	5,424,205	6/13/95	Dovey et al.	435	226	
	A2	5,593,846	1/14/97	Schenk et al.	435	7.9	
	A3	5,733,768	3/31/98	Dixon et al.	435	226	
	A4	5,744,346	4/28/98	Chrysler et al.	435	226	
	A5	5,750,349	5/12/98	Suzuki et al.	435	7.1	
	A6	5,766,846	6/16/98	Schlossmacher et al.	435	6	
	A7	5,837,672	11/17/98	Schenk et al.	514	2	
	A8	5,849,560	12/15/98	Abraham	435	219	
	A9	5,942,400	8/24/99	Anderson et al.	435	7.1	
	A10	6,025,180	2/15/00	Powell et al.	435	219	
	A11	5,455,169	10/3/95	Mullan	435	240.2	ļ
	A12	5,795,963	8/18/98	Mullan	435	350	
	A13	5,877,015	3/2/99	Hardy et al.	435	325	
 	A14	6,211,428	4/3/01	Singh et al.	800	13	
	A15	6,221,645	4/24/01	Chrysler et al.	435	226	
	A16	6,245,884	6/12/01	Hook	530	300	
 	A17	6,245,964	6/12/01	McLonlogue et al.	800	12	
1-1-	A18	60/141,363	N/A	Lin et al.	+ 300	 	6/28/99
	A19	60/168,060	N/A	Lin et al.	 	 	11/30/99
	A20	60/178,368	N/A	Lin et al.			1/27/00
	A21	60/210,292	N/A	Hong et al.			6/8/00
	A22	09/277,229	N/A	Citron et al.			3/26/99
	A23	6,313,268	11/6/01	Hook	530	350	
	A24	60/177,836	N/A	Lin et al.			1/25/00
	A25	60/119,571	N/A	Basi et al.			2/10/99
	A26	60/139,172	N/A	Anderson et al.			6/15/00
	A27	60/114,408	N/A	Basi et al.			12/13/98
	A28	09/404,578	N/A	Chrysler et al.			9/23/99
	A29	09/054,334	N/A	Anderson et al.			4/2/98
	A30	09/730,329	N/A	Anderson et al.			12/4/00
	A31	09/471,669	N/A	Anderson et al.		_	12/24/99
ļ. <u>.</u>	A32	09/501,708	N/A	Anderson et al.			12/10/00
	A33	09/723,722	N/A	Anderson et al.			11/28/00
 	A34	09/724,566	N/A	Anderson et al.	_		11/28/00
	A35	09/723,739	N/A	Anderson et al.			11/28/00
 	A36	09/724,571	N/A	Anderson et al.		- 	11/28/00
	A37	09/724,568	N/A	Anderson et al.			11/28/00
├ ─ ₩	A38	09/724,569	N/A	Anderson et al.	425	1.0.	11/28/00
	A39	6,319,489	11/20/01	Powell et al.	435	69.1	

EXAMINER /Gregory Emch/ DATE CONSIDERED 09/21/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

Attorney Docket No. 29915/6280N3 10/652,927 Applicant Gurney et al. Filing Date Group 1649 August 29, 2003

INFORMATION DISCLOSURE STATEMENT

			U.S. PA	TENT DOCUMENTS	<u> </u>		
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
GE	A40	6,162,630	12/19/00	Powell et al.	435	219	
1	A41	6,319,689	11/20/01	Powell et al.	· 435	69.1	
	A42	6,358,725	03/19/02	Christie et al.	435	212	
1/	A43	6,361,975	03/26/02	Christie et al.	435	69.1	
	A44	6,545,127	04/08/03	Tang et al.	530	350	

		FOR	EIGN PATENT	DOCUMEN	ITS			
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Trans	ation
					l		Yes	No
GE	B1 €	WO 96/31122	10/10/96	PCT				
1	B2 %	WO 96/40885	12/19/96	PCT				
	B3 🛧	WO 98/13488	4/2/98	PCT				
	B4 *	WO 98/21589	5/22/98	PCT				
	B5 →	EP 0848 062 A2	6/17/98	EPO				
	B6 🔭	WO 98/26059	6/18/98	PCT				
	B7-X	EP 0855 444 A2	7/29/98	EPO				
	B8 x	WO 99/34004	8/7/99	PCT				
	B9 🖟	WO 99/31236	6/24/99	PCT				
	B101/	WO 99/46281	9/16/99	PCT				
	B11%	WO 99/64587	12/16/99	PCT				
	B12 🖟	WO 00/23576	4/27/00	PCT				
	B13-	WO 00/47618	08/17/00	PCT				
	B14 X	WO 00/58479	10/05/00	PCT				
	B157	WO 00/56871	9/28/00	PCT				
	B16/4	WO 00/68266	11/16/00	PCT				
	B17-£	WO 00/69262	11/23/00	PCT				
1	B18-6/	WO 01/00663	1/4/01	PCT ·				
	B19.	WO 01/00665	1/4/01	PCT				
	B20 x	WO 01/29563	4/26/01	PCT				
	B21+	WO 01/31054	5/3/01	PCT				
1/	B22 *	WO 01/36600	5/25/01	PCT				
V	B23	WO 01/38487	5/31/01	PCT				

	OTH	ER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
GE	CI *	Chyung et al. Novel β-Secretase Cleavage of β-Amyloid Precursor Protein in the Endoplasmic Reticulum/Intermediate Compartment of NT2N Cells, <i>Journal of Cell Biology</i> , 138: 671-680 (1997).
140450		L D. IIII COLLONDO

EXAMINER

/Gregory Emch/

DATE CONSIDERED 09/21/2006

[•]EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trudemark Office

Attorney Docket No.	Serial No.			
29915/6280N3 10/652,927				
Applicant	···			
Gurney et al.				
Filing Date	Group	1649		
August 29, 2003	1645	. TO43		

INFORMATION DISCLOSURE STATEMENT

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)					
GE	C2	Evin et al., Alzheimer's disease amyloid precursor protein (AβPP): proteolytic processing, secretases and βA4 amyloid production, <i>Amyloid</i> ; <i>Int. J. Exp. Clin. Invest.</i> , 1: 263-280 (1997).				
	C3 ★	Haass et al., Amyloid β-peptide is Produced by Cultured Cells During Normal Metabolism, Nature, 359: 322-325 (1992).				
	C4	Haass et al., β-Amyloid Peptide and 3-kDa Fragment are Derived by Distinct Cellular Mechanisms, Journal of Biochemistry, 268: 3021-3024 (February 15, 1993).				
	C5 K	Haass et al., The Swedish Mutation Causes Early-Onset Alzheimer's Disease by β-Secretase Cleavage Within the Secretory Pathway, <i>Nature Medicine</i> , 12: 1291-1296 (1995).				
	C6*	Hirosawa et al., Characterization of cDNA Clones Selected by the GeneMark Analysis from Size-Fractionated cDNA Libraries From Human Brain, DNA Res., 6(5): 329-336 (1999).				
	C7 *	Hussain et al., Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase, Molecular and Cellular Neuroscience, 14: 419-427 (1999).				
	C8 /	Kang et al., The Precursor of Alzheimer's Disease Amyloid A4 Protein Resembles a Cell-Surface Receptor, <i>Nature</i> , 325: 733-736 (1987).				
	C9 *	Kitaguchi et al., Novel Precursor of Alzheimer's Disease Amyloid Protein Shows Protease				
	C10	Knops et al., Cell-type and Amyloid Precursor Protein-type Specific Inhibition of Aβ Release by Bafilomycin A1, a Selective Inhibitor of Vacuolar ATPases, <i>Journal of Biological Chemistry</i> , 270: 2419-2422 (1995).				
	C11*					
	C12	Ponte et al., A New A4 Amyloid mRNA Contains a Domain Homologous to Serine				
	C13	Seubert et al. Secretion of β-amyloid Precursor Protein Cleaved at the Amino Terminus of				
	C14					
	C15+c	Szecsi, The Aspartic Proteases, Scand. J. Clin. Lab. Invest., 52 (suppl. 210): 5-22 (1992).				
	C16 ×	Tanzi et al., Protease Inhibitor Domain Encoded by an Amyloid Protein Precursor mRNA Associated with Alzheimer's Disease, <i>Nature</i> , 331: 528-530 (1988).				
	C17	Vasser et al., β-secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE, Science, 286 (5440): 735-41 (1999).				
	C18	Yan et al., Membrane-anchored Aspartyl Protease with Alzheimer's Disease β-Secretase Activity, Nature, 402: 533-537 (1999).				
	C19	Zhao et al., β-Secretase Processing of the β-Amyloid Precursor Protein in Transgenic Mice Is Efficient in Neurons but Inefficient in Astrocytes, <i>Journal of Biological Chemistry</i> , 271: 31407-31411 (1996).				
	C201/k					
	C21/X	Mullan et al., A Pathogenic Mutation for Probable Alzheimer's Disease in the APP Gene at the N-Terminus of β-Amyloid, Nature Genetics 1: 345-347 (1992).				
V	C22-5	Elan and Pharmacia form Alzheimer's disease research collaboration in the area of Beta- Secretase, News 08/09/2000, www.elancorp.com.				

EXAMINER /Gregory Emch/ DATE CONSIDERED 09/21/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.